Jun A, Bau S, Kim J, Phillips S
Nurse Pract. 2024; 50(1):7-13.
PMID: 39696735
PMC: 11658015.
DOI: 10.1097/01.NPR.0000000000000246.
Liu S, Yang X
Front Cell Infect Microbiol. 2023; 13:1140126.
PMID: 36968098
PMC: 10034054.
DOI: 10.3389/fcimb.2023.1140126.
Xuan Hoan N, Huyen P, Binh M, Trung N, Giang D, Linh B
Sci Rep. 2021; 11(1):7772.
PMID: 33833369
PMC: 8032722.
DOI: 10.1038/s41598-021-87537-9.
Tang R, Lei Z, Wang X, Qi Q, He J, Liu D
Exp Ther Med. 2020; 20(4):3679-3686.
PMID: 32855720
PMC: 7444405.
DOI: 10.3892/etm.2020.9107.
Trujillo H, Blanco A, Garcia D, Freyre F, Aguiar J, Lobaina Y
Euroasian J Hepatogastroenterol. 2018; 4(2):70-78.
PMID: 29699351
PMC: 5913899.
DOI: 10.5005/jp-journals-10018-1105.
Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.
Cho H, Kang H, Lee H, Kim C
Int J Mol Sci. 2017; 18(7).
PMID: 28703774
PMC: 5536007.
DOI: 10.3390/ijms18071517.
Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X, Li J, Liu J, Gao M, Zhou L, Lu W
Medicine (Baltimore). 2017; 96(23):e7064.
PMID: 28591041
PMC: 5466219.
DOI: 10.1097/MD.0000000000007064.
Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection.
Dong J, Yang X, Wang L, Wei X, Wang A, Hao C
Front Cell Infect Microbiol. 2017; 7:98.
PMID: 28401068
PMC: 5368241.
DOI: 10.3389/fcimb.2017.00098.
Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B.
Chen Y, Huang Z, Ma D, Chen L, Lai Q, Huang X
BMC Immunol. 2015; 16:29.
PMID: 25982058
PMC: 4434833.
DOI: 10.1186/s12865-015-0088-x.
Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.
Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y
Mediators Inflamm. 2012; 2012:789859.
PMID: 22570512
PMC: 3337496.
DOI: 10.1155/2012/789859.
New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response.
Ratnam D, Visvanathan K
Hepatol Int. 2009; 2(Supplement 1):12-8.
PMID: 19669294
PMC: 2716839.
DOI: 10.1007/s12072-008-9067-0.
Emerging drugs for hepatitis B.
Zoulim F
Expert Opin Emerg Drugs. 2007; 12(2):199-217.
PMID: 17604497
PMC: 3194402.
DOI: 10.1517/14728214.12.2.199.
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy.
Webster G, Reignat S, Brown D, Ogg G, Jones L, Seneviratne S
J Virol. 2004; 78(11):5707-19.
PMID: 15140968
PMC: 415806.
DOI: 10.1128/JVI.78.11.5707-5719.2004.
